Proceeds to Help Fund Institute’s Groundbreaking Research and New Facilities
LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers. Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.
TORRANCE, Calif., May 24, 2017 /PRNewswire/ -- Emmaus Life Sciences Inc. announced today that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of EndariTM for the treatment of sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date for July 7, 2017.
LOS ANGELES – (May 18, 2017) – LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers.
Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.
LA BioMed Researcher Honored for Outstanding Work in Liver Disease
The Research Society on Alcoholism (RSA), an organization of researchers who specialize in the study of alcoholism, will honor Samuel W. French, MD, a lead researcher at LA BioMed, with its prestigious 2017 Lifetime Achievement Award for his outstanding work in the field of alcohol research at the organization’s annual scientific meeting in Denver on June 28.
March 9 event features presentations of the latest in breakthrough technologies
On March 9, LA BioMed will host its Fourth Annual Innovation Showcase featuring a full day of break-through technology presentations and speakers that will address issues surrounding the commercialization of technologies.
The showcase at the Manhattan Beach Marriott is expected to attract more than 300 entrepreneurs, investors, executives from biotech and pharma medical devices companies, legal experts, service providers, prominent scientists and technology transfer
New JAMA Study Finds an Increase in Arterial Plaque
A new study suggests testosterone treatments may increase the risk of heart disease in older men. It found a 20% increase in arterial plaque among men aged 65 and older who received testosterone replacement therapy for a year, according to the study published today in the Journal of the American Medical Association (JAMA).
LA BioMed among the institutions that participated in extensive studies of testosterone treatments
Research published today found testosterone treatment improved bone density and anemia for men over 65 with low testosterone. But the treatment didn’t improve patients’ cognitive function, and it increased the amount of plaque buildup in participants’ coronary arteries, according to four studies published in the Journal of the American Medical Association (JAMA) and JAMA Internal Medicine.
Intensive Care Units (ICUs), which provide the most expensive and invasive forms of care in a hospital setting, are being used too often for patients who don’t need that level of care, according to a new study by LA BioMed and UCLA researchers published in the Journal of the American Medical Association Internal Medicine today.
The researchers studied 808 ICU admissions from July 1, 2015 to June 15, 2016 at Harbor-UCLA Medical Center and found that more than half the patients could have been cared for in less expensive and invasive settings.
Study finds low-cost eye drops equal in effectiveness to more costly antibiotics
Bacterial keratitis, an infection of the cornea often caused by contact lenses, malnutrition, or an injury, can lead to corneal scarring, one of the leading causes of blindness around the globe, according to the World Health Organization. It has blinded more than 400,000 children worldwide.